ArticleBMC gastroenterology2026
Integrating WGCNA and machine learning to identify and validate key biomarkers in MASLD.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) represents the most prevalent chronic liver disease worldwide. The absence of approved pharmacotherapies is largely attributed to their profound molecular heterogeneity. The identification of novel hub genes in MASLD is therefore critical for unraveling the complex molecular mechanisms driving disease pathogenesis and progression.
methodsWe employed an integrative systems-biology approach utilizing Weighted Gene Co-expression Network Analysis (WGCNA) followed by multi-algorithm machine learning (LASSO, Random Forest, SVM-RFE) across GEO datasets (GSE89632, GSE63067) to identify hub genes. Key hub genes were validated in vitro with FFA-treated HepG2 cells and in vivo with an HFD-fed mouse model.
resultsBioinformatic analyses revealed two distinct pathological networks. First, a lipogenesis-associated cluster revealed FMO1 and C10orf140 as upregulated, alongside JUNB downregulation. In vitro, the expression of these genes was significantly associated with the activation of the SREBP-1c/FASN lipogenic pathway. Second, WGCNA revealed a co-expression module that exhibited high correlation with inflammation (R = 0.59, p = 4e-05), from which 11 hub genes relating to inflammation (such as MAP3K8, PFKFB3) were identified. In vivo, HFD mice developed severe steatosis and demonstrated a key pathological paradox: high-level activation of both the pro-lipogenic p-AKT and the inhibitory p-AMPK pathways.
conclusionOur study identified the hub genes FMO1, C10orf140, and JUNB as novel regulators of MASLD lipogenesis through the SREBP-1c pathway. Additionally, we showed that co-activated p-AKT and p-AMPK in steatotic livers indicates "AMPK Resistance". Ultimately, we describe a mechanism of pro-lipogenic signaling that is not curtailed and is accompanied by the inability to compensate for the inhibitory path. All findings reveal potential therapeutic targets for MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.